Combination of | |
---|---|
Glycopyrronium bromide | Muscarinic anticholinergic |
Formoterol | Long-acting β2 agonist (LABA) |
Clinical data | |
Trade names | Bevespi Aerosphere |
AHFS/ Drugs.com | Monograph |
License data | |
Routes of administration | By mouth (inhalation) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [2] [3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled. [2] [3]
The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness. [3]
Glycopyrronium bromide is a muscarinic receptor antagonist. [3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. [3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open. [3]
Formoterol is a long-acting beta-2 agonist. [3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. [3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open. [3]
Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). [3]
Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016, [4] and in the European Union in December 2018. [3]
It is marketed by AstraZeneca. [2] [3]